Evidence map›Paper›PMID 40475856›Full record

ArticleMaterials today. Bio2025

A pH/MMP-9 smart dual-responsive liposome GBE@LP co-delivers and controls the release of GB1107/BMS1166/Enzalutamide for liver cancer immunotherapy.

Shijia Lu, Chenxiao Zhang, Huiru Wu, Junjie Wang, Jinglong Wang, Limei Zhao, Tianyang Ren, Guofei Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. The Role of Galectin-3 in Liver Inflammation and Fibrosis.Journal of inflammation research · 2026
    Review
  7. The Immune Microenvironment in Liver Cancer: From Analysis to Targeting.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shijia LuShengjing Hospital of China Medical University, Department of Pharmacy, No. 36, Sanhao Street, Shenyang, 110004, China.
Chenxiao ZhangShengjing Hospital of China Medical University, Department of Pharmacy, No. 36, Sanhao Street, Shenyang, 110004, China.
Huiru WuShengjing Hospital of China Medical University, Department of Pharmacy, No. 36, Sanhao Street, Shenyang, 110004, China.
Junjie WangShengjing Hospital of China Medical University, Department of Pharmacy, No. 36, Sanhao Street, Shenyang, 110004, China.
Jinglong WangShengjing Hospital of China Medical University, Department of Pharmacy, No. 36, Sanhao Street, Shenyang, 110004, China.
Limei ZhaoShengjing Hospital of China Medical University, Department of Pharmacy, No. 36, Sanhao Street, Shenyang, 110004, China.
Tianyang RenShengjing Hospital of China Medical University, Department of Pharmacy, No. 36, Sanhao Street, Shenyang, 110004, China.
Guofei LiShengjing Hospital of China Medical University, Department of Pharmacy, No. 36, Sanhao Street, Shenyang, 110004, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver cancer is one of the malignant tumors with high morbidity and mortality worldwide and lacks effective clinical treatments. CD8

Indexed as

Cancer immunotherapyCombination therapyICBIntelligent materialLiposome drug delivery systemLiver cancer

Identifiers

PMID40475856
PMCPMC12139023

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.